Mild cognitive impairment
Conditions
Interventions
VD3 intervention group:Pure VD3 intervention at 800IU/day (400IU/capsule, 2 capsules/day) and DHA placebo capsule at 1 capsule/day.
DHA intervention group:DHA soft capsules 1g/day (1g/capsule, 1 capsule/day) and VD3 placebo 2 capsules/day.
VD3 combined with DHA intervention group:VD3 intervention at 800IU/day (400IU/capsule, 2 capsules/day) and DHA soft capsules at 1g/day (1g/capsule).
Placebo control group:2 VD3 placebo capsules per day and 1 DHA placebo capsule per day.
Sponsors
Tianjin Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Participants subjectively believe or are objectively confirmed by family members/doctors to have memory impairment; 2. Memory impairment lasts for at least three months; 3. The Mini Mental State Examination (MMSE) score is>= 17 for the illiterate group, >= 20 for the primary school group, and >=24 for the middle school and above group; According to the Activities of Daily Living Scale, if there is no or slight impairment in daily living activities, the ADL score is <= 18 points; 5. Not suitable for dementia AD The criteria for mental illness, brain injury, or any active neuropsychiatric disorder that may lead to cognitive impairment. The diagnostic criteria for dementia are based on the DSM-IV criteria of the American Psychiatric Association and the National Institute of Neurology, Language Disorders, and Stroke Alzheimer's and Related Disorders (NINCDS-ADRDA) criteria, combined with medical history and other data for dementia diagnosis. Using HIS to differentiate between AD and vascular dementia. Suspected MCI and senile dementia patients will be further diagnosed by neurologists.
Exclusion criteria
Exclusion criteria: 1. Clinical diagnosis of AD, PD or other dementia; 2. Having serious organ dysfunction, malignant tumors, or other major diseases that can affect cognitive function; 3. Have taken nutritional supplements that interfere with vitamin D3 or DHA metabolism within the past 3 months prior to recruitment. 4. Medical conditions that prohibit the use of vitamin D3 or DHA.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Full intelligence quotient; | — |
Secondary
| Measure | Time frame |
|---|---|
| AD related biomarkers (APP, PS1,PS2);Proinflammatory cytokine(IL-1ß, IL-18, Aß40, Aß42);NLRP3 inflammasome pathway related proteins(NLRP3, GSDMD, caspase-1);Basic Information of the Research Subjects; | — |
Countries
China
Contacts
Public ContactFei Ma
Tianjin Medical University
Outcome results
None listed